



US005120760A

United States Patent [19]
Horrobin

[11] **Patent Number:** **5,120,760**
[45] **Date of Patent:** * **Jun. 9, 1992**

[54] **TREATING TARDIVE DYSKINESIA WITH ESSENTIAL FATTY ACID COMPOSITIONS**

[75] **Inventor:** David F. Horrobin, Guildford, England

[73] **Assignee:** Efamol Holdings PLC, Surrey, England

[*] **Notice:** The portion of the term of this patent subsequent to Dec. 11, 2007 has been disclaimed.

[21] **Appl. No.:** 591,604

[22] **Filed:** Sep. 25, 1990

Related U.S. Application Data

[62] Division of Ser. No. 359,565, Jun. 1, 1989, Pat. No. 4,977,187.

[30] **Foreign Application Priority Data**

Jun. 10, 1988 [GB] United Kingdom 8813766

[51] **Int. Cl.⁵** **A61K 31/20; A61K 31/355**

[52] **U.S. Cl.** **514/458; 514/560**

[58] **Field of Search** 514/458, 560

[56] **References Cited**

U.S. PATENT DOCUMENTS

4,273,763 6/1981 Horrobin 514/560
4,302,447 11/1981 Horrobin 514/560

4,738,985 4/1988 Kluger et al. 514/533
4,780,456 10/1988 Pistolessi 514/560
4,826,877 5/1989 Stewart et al. 514/560
4,977,187 12/1990 Horrobin 514/560

FOREIGN PATENT DOCUMENTS

0115419 8/1984 European Pat. Off. .
0234733 9/1987 European Pat. Off. .
0296751 12/1988 European Pat. Off. .
3719097 6/1988 Fed. Rep. of Germany .
1082624 9/1967 United Kingdom .
2148713 6/1985 United Kingdom .

Primary Examiner—Frederick E. Waddell
Assistant Examiner—K. Weddington
Attorney, Agent, or Firm—Nixon & Vanderhye

[57] **ABSTRACT**

Method of, and preparations of medicaments for, treating schizophrenia and/or associated tardive dyskinesia by combining an essential fatty acid selected from GLA and higher n-6 series acids with an essential fatty acid selected from stearidonic acid and higher n-3 series acids in effective daily amounts of 10 mg and 50 g of each acid.

3 Claims, No Drawings